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Abstract
Background: Germline mutations in the DNA mismatch repair genes predispose to Lynch syndrome, thus
conferring a high relative risk of colorectal and endometrial cancer. The MLH1, MSH2 and MSH6 mutational
spectrum reported so far involves minor alterations scattered throughout their coding regions as well as large
genomic rearrangements. Therefore, a combination of complete sequencing and a specialized technique for the
detection of genomic rearrangements should be conducted during a proper DNA-testing procedure. Our main
goal was to successfully identify Lynch syndrome families and determine the spectrum of MLH1, MSH2 and MSH6
mutations in Greek Lynch families in order to develop an efficient screening protocol for the Greek colorectal
cancer patients’ cohort.
Methods: Forty-two samples from twenty-four families, out of which twenty two of Greek, one of Cypriot and one
of Serbian origin, were screened for the presence of germline mutations in the major mismatch repair genes
through direct sequencing and MLPA. Families were selected upon Amsterdam criteria or revised Bethesda
guidelines.
Results: Ten deleterious alterations were detected in twelve out of the twenty-four families subjected to genetic
testing, thus our detection rate is 50%. Four of the pathogenic point mutations, namely two nonsense, one
missense and one splice site change, are novel, whereas the detected genomic deletion encompassing exon 6 of
the MLH1 gene has been described repeatedly in the LOVD database. The average age of onset for the
development of both colorectal and endometrial cancer among mutation positive families is 43.2 years.
Conclusion: The mutational spectrum of the MMR genes investigated as it has been shaped by our analysis is
quite heterogeneous without any strong indication for the presence of a founder effect.
Background
Colorectal cancer (CRC) is the second most common
cause of cancer-related deaths in the industrialized
countries [1]. Approximately 5 to 10% of all colorectal
cancer cases are due to highly penetrant alleles, which
are inherited mostly in an autosomal dominant
fashion [2].
Lynch syndrome, also referred to as Hereditary Non
Polyposis Colorectal Cancer (HNPCC), is the most com-
mon hereditary colon cancer syndrome [1]. However, its
actual tumour spectrum is quite heterogeneous. Particu-
larly, it confers high susceptibility to the development of
cancer in the female reproductive tract [3], while the
risk for developing cancer at other organs such as ovar-
ies, stomach, small bowel, brain and urinary tract ranges
from 2% to 13% [4]. It is attributed to germline muta-
tions in either of the mismatch repair (MMR) genes:
MLH1, MSH2, MSH6 and PMS2 [5]. The main function
of the MMR gene products is to identify and correct
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any medium, provided the original work is properly cited.mismatches as well as short insertion or deletion loops,
which occur during replication and recombination [6].
In case of disabled MMR machinery, errors resulting to
the contraction/expansion of tandemly repeated
sequences, known as microsatellites, accumulate. This
condition is termed as microsatellite instability (MSI).
Detection of MSI has been a useful prescreening labora-
tory tool for the recognition of suspected Lynch syn-
drome cases [2,7].
In clinical practice, the diagnosis of Lynch syndrome is
mainly based on the Amsterdam criteria (AMS) [8]. How-
ever, families of small size or with atypical features, such
as later age of onset for CRC, might be missed if only the
AMS criteria are taken into consideration. Therefore, the
Bethesda guidelines, which include all clinical conditions,
have emerged as criteria of suspicion [2,8].
The selection of the actual “high-risk” patients is a
matter of significance, as a proper genetic testing should
combine sequencing of the MMR gene coding regions
with techniques for the detection of large genomic rear-
rangements. This is so, because no hotspots have been
reported in the MMR genes while deletions/duplications
account for a substantial part of mutations associated
with Lynch syndrome [9-11]. Nevertheless, the presence
of founder mutations have been well documented in
some populations, thus facilitating the procedure of
genetic testing [1].
The aim of this study was to successfully identify
Lynch syndrome families and to report the MLH1,
MSH2 and MSH6 mutational spectrum within Greek
colorectal cancer families. More specifically, the nature
and frequency of the pathogenic alterations has been
elucidated in order to develop an efficient DNA-based
screening protocol for the Greek colorectal cancer
patients’ cohort.
Methods
Patients
The Amsterdam criteria and the revised Bethesda
guidelines were used as selection criteria. Ultimately,
twenty-four families were subjected for genetic testing, i.e.
monitoring of point mutations or large genomic rearran-
gements in MLH1, MSH2 and MSH6 genes. Seventeen of
the selected families fulfilled the Amsterdam criteria while
seven families satisfied at least one of the revised Bethesda
guidelines. All families were referred to Molecular Diag-
nostics Laboratory - NCSR “DEMOKRITOS”. All patients
gave us written informed consent for participation in our
study. The study was approved by the Bioethics Commit-
tee of the National Centre for Scientific Research “Demok-
ritos” (Reference Number 240/EHΔ/10.8) in agreement
with the 1975 Helsinki statement, revised in 1983.
An additional 951 sporadic colorectal cancer cases,
collected from Hellenic Community of Oncology
(HECOG), were screened for the genomic rearrange-
ment identified, resulting in the deletion of exon 6 of
MLH1 gene.
DNA extraction
Total genomic DNA was isolated from peripheral blood
lymphocytes following the salt extraction procedure
[12]. The quantity and quality of the DNA samples was
determined with “NanoDrop” (Thermo Fisher Scientific,
MA, USA).
DNA sequencing
All exons of the MLH1, MSH2 and MSH6 genes, includ-
ing splice junctions, were amplified by polymerase chain
reaction (PCR). The PCR products were purified with
“Nucleofast 96 PCR Plates” (Macherey-Nagel, Germany)
and then subjected to automated cycle sequencing with
the Big Dye Terminator Cycle v3.1 sequencing kit
(Applied Biosystems, Foster City, CA) and electrophor-
esis on an ABI Prism 310 Sequencer (PerkinElmer,
Applied Biosystems, Foster City, CA). Primer pairs were
designed with “Primer 3” software and are available
upon request.
RNA extraction and RT-PCR
Total RNA was extracted from peripheral blood lym-
phocytes using Trizol (Invitrogen, Paisley, UK) following
standard protocol. 1000 ng of total RNA was reverse
transcribed using 60 μM of random hexamers and 10
units of MMLV reverse transcriptase (Roche Diagnos-
tics, Mannheim, Germany) at 50°C for 30 min, followed
by enzyme inactivation at 85°C for 5 min. Subsequently,
cDNA was amplified on a new PCR reaction using the
proper primer set.
Multiplex Ligation-Dependent Probe Amplification (MLPA)
MLPA was performed with P003 kit (MRC-Holland,
Netherlands) according to the manufacturer’si n s t r u c -
tions. Fragment analysis was conducted on ABI Prism
310 Genetic Analyzer using GeneMapper software
(Applied Biosystems, Foster City, CA). 35 peaks corre-
sponding to each exon of the MLH1 and MSH2 genes, as
well as 7 peaks corresponding to DNA sequences outside
these genes, were identified. Their migration was calcu-
lated according to the GeneScan ROX-500 size standard
(Applied Biosystems, Foster City, CA). Decrease of 30 to
50% in the peak area(s) was considered as deletion of the
corresponding exon(s), while increase of 30 to 50% as
duplication of the corresponding exon(s).
Long range polymerase chain reaction and breakpoint
analysis
150 ng of genomic DNA was amplified in a 50 μl reac-
tion volume using 1,5 mM Mg
+2,3 0 0μM of each
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Diagnostics). Primers were designed between exon 5
and intron 7 of the MLH1 gene. Cycling conditions
were as follows: 94°C for 2 min, 94°C for 15 sec/62°C
for 30 sec {-5°C/cycle}/68°C for 5 min {×14 cycles}, 94°C
for 15 sec/55°C for 30 sec/68°C for 5 min {×20 cycles},
68°C for 15 min. The PCR product was further ampli-
fied using various primer pairs in a 20 μl reaction.
Cycling conditions were: 95°C for 2 min, 95°C for 25
sec/59°C for 30 sec/72°C for 2 min {×25 cycles}, 72°C
for 5 min. The PCR products were finally subjected to
sequencing.
PCR using diagnostic primers
100 ng of genomic DNA was amplified in a 20 μl reac-
tion volume using 1.5 mM Mg
+2,1 0 0μM of each
dNTP, 1.25 U of Taq polymerase (HyTest Ltd. Intelli-
gate, Finland). Two primer sets were used (F3/R1 &
For/Rev ×15 BRAF) in order to achieve the simulta-
neous amplification of the locus involving the exon 6
deletion and an independent locus used as an internal
control [13,14]. Cycling conditions were as follows: 95°C
for 3 min, 95°C for 30 sec/59°C for 30 sec/72°C for 45
sec {×35 cycles}, 72°C for 7 min.
Results
Mutational analysis
Twenty-four probands were screened for the presence of
point mutations and large genomic rearrangements in
either MLH1, MSH2 or MSH6 genes. Subsequently, when
a pathogenic mutation was identified, family relatives were
screened for the presence of the particular mutation. In
total, forty-two samples were subjected to genetic testing.
MLPA analysis was performed only in probands that
tested negative for point alterations. Seventeen families
fulfilled the Amsterdam criteria, while the remaining satis-
fied one or more of the revised Bethesda guidelines (age of
onset < 50y, 1
st degree relatives diagnosed with CRC).
Twelve out of the twenty-four families found to carry
pathogenic mutations in the mismatch repair genes
(MLH1, MSH2 and MSH6) studied. Interestingly, all
families that carry a pathogenic mutation fulfilled the
Amsterdam criteria, whereas none of the families fulfill-
ing at least one of the Bethesda guidelines carry deleter-
ious aberration in the investigated genes.
A detailed family history along with the clinical data
of each proband harboring a deleterious mutation is
presented on table 1. The pathogenic mutations identi-
fied in twelve families are summarized on Table 2.
Table 1 Features of families carrying a germline mutation in either of the MMR genes
Patient
ID
Clinical manifestations
(age of onset)
Family history Criteria used
for selection
F33 Endometrial Ca (40) mother hysterectomy at 40y-CRC at 70y, 1
st brother CRC at 50y, 2
nd brother CRC at 32y AMS II
F39 CRC (50) father stomach Ca at 64y, sister ovarian Ca at 56y, one 2
nd degree relative (P) brain Ca at
47y, one 2
nd degree relative (P) pancreatic Ca at 58y, 2 2
nd degree relatives (P) CRC at 52y &
80y respectively
AMS II
F41 Endometrial Ca (~45)-
CRC (77)
1 daughter endometrial Ca at 45y- CRC at 58y,1 grandson died from CRC at 29y, 1
granddaughter <5 polyps at 33y, two brothers CRC >50y, 1 sister endometrial Ca at 26y, 1
niece endometrial Ca at 40y
AMS II
F74 CRC (42)- endometrial Ca
(64)
mother endometrial Ca- CRC, brother CRC at 26y, grandmother (M) CRC, uncle (M) CRC at
37y- CRC at 54y, cousin (M) CRC at 40y
AMS II
F84 Endometrial Ca (40) mother died from pulmonary embolism, grandmother (M) stomach Ca at 60y, 2 2
nd degree
relatives CRC, 1 2
nd degree relative CRC-metachronous endometrial Ca
AMS II
F263 CRC (42)-
metachronous CRC (47)
mother endometrial Ca at 50y, grandfather (M) stomach Ca, 4 2
nd degree relatives CRC, 1
2
nd degree relative endometrial Ca at 34y
AMS II
F111 CRC (42) father renal Ca-prostate Ca, grandfather (P) CRC, uncle (P) CRC Revised
Bethesda
F150 CRC (40) father CRC at 48y, uncle (P) CRC at 50y AMS I
F656 CRC (59) father CRC at 41y, 1
st sister CRC at 41y, 2
nd sister CRC at 65y, grandmother (P)
gynecological Ca at ?y
AMS II
F1278 CRC (33) father CRC at 56y, grandmother (P) gynecological Ca at ?y- CRC at ~43y AMS II
F68 CRC (28)-
metachronous CRC (44)
father prostate Ca, brother 4 polyps at 36y,12
nd degree relative CRC at 45y-metachronous
CRC at 80y, 12
nd degree relative duodenum adenoCa at 42y
Revised
Bethesda
F1376 Ca cecum (30) mother CRC at 50y-polyp in the female reproductive tract at ~45y, grandfather (M) CRC at
~80y, 5 2
nd degree relatives CRC <60y, 1 2
nd degree relative endometrial Ca at ~50y-
metachronous CRC at 65y
AMSII
1SRB
(Serbian
origin)
CRC (49) father CRC at 60y, 2 brothers CRC at 49 & 59y respectively, 1 sister endometrial Ca at 48y-
metachronous CRC at 57y, 1 sister pancreatic Ca at 63y, 1 niece CRC-synchronous stomach
Ca at 25y, 2 2
nd degree relatives (P) CRC at 50 & 60y respectively, 1 2
nd degree relative (P)
bladder Ca at 60y
AMSII
*Family members written in bold italic carry the particular mutation running in the family **(P): Paternal, (M): Maternal, CRC: ColoRectal Cancer, Ca: Cancer.
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Page 3 of 12Three of the pathogenic nucleotide substitutions
located in exons 5, 7 and 13 of the MSH2 gene resulted
i nap r e m a t u r es t o pc o d o n .T h en o n s e n s em u t a t i o n s
MSH2, p.Gln314X (exon 5) and p.Gln413X (exon 7) are
novel, to the best of our knowledge. The MSH2,p .
Arg711X (exon 13) has been reported several times in
the LOVD database, as well as in an older study con-
ducted in Greek colorectal cancer patients [15].
Two splice site changes were detected in four separate
families. RT-PCR analysis of the MLH1, c.116+5G > C
mutation, which is located in intron 1, results in a 227-
base pair insertion taking place between exons 1 and 2
(data not shown). The specific mutation has been
reported twice in the literature, while both bioinformatic
prediction tools and in vitro techniques (conversion/
c D N Aa n a l y s i s )d e m o n s t r a t e dt h a ti ta c t i v a t e sac r y p t i c
splice site [16,17]. On the other hand, the MLH1, c.790
+1G > A mutation, which is located in intron 9, induces
skipping of exons 9 and 10 [18]. This mutation was
identified in two distinct families, one of Greek and one
of Cypriot origin. Thirteen different cancer cases have
been reported in the Cypriot family, all potentially
r e l a t e dt oL y n c hs y n d r o m e .H o w e v e r ,o n eo ft h ep r o -
band’s daughters, who developed breast cancer at the
age of 42 years, does not carry the particular mutation.
The detailed family pedigree is shown on figure 1.
Moreover, direct sequencing of DNA from samples
F1278 and 1SRB revealed thep r e s e n c eo ft w od i s c r e t e
missense changes located in exon 13 of the MSH2 gene.
Exons 7 to 13 of the MSH2 g e n es p a nt h eh i g h l yc o n -
served ABC-ATPase domain, thus amino acid substitu-
tions in this domain may have a severe impact on the
protein’sf u n c t i o n[ 1 9 ] .T h eMSH2, p.Cys759Arg is
characterized as pathogenic in the “MMR Gene Unclas-
sified Variants Database” http://www.mmrmissense.info/.
The MSH2, p.Arg711Pro mutation, which was identified
in a Serbian family, is reported for the first time and its
pathogenicity was assessed through bioinformatics tools
(Table 3). All the protein web tools used (SIFT, Poly-
P h e n ,M A P P - M M R[ 2 0 ] )c o n c l u d et h a ti ti sad e l e t e r -
ious change. In addition, it may influence the splicing
process through the abrogation/creation of enhancer/
silencer motifs as prediction algorithms for the presence
of such sequences have demonstrated (Table 3).
The MSH2, c.1276G > C involves a novel G to C
transversion located at the last nucleotide of the exon 7
of the MSH2 g e n e .A c c o r d i n gt ot h ein silico analysis
performed, the wild type splice donor is abolished
(Table 4). Furthermore, the majority of the algorithms
used for the prediction of enhancer/silencer motifs by
the Human Splice Finder (v.2.4) web tool http://www.
umd.be/HSF/[21] indicate that the c.1276G > C induces
the abrogation or creation of such binding sites.
The MSH6, c.3202 C > T mutation, located on exon 5
of the gene, has been identified in an individual diag-
nosed with colorectal cancer at the age of 40. The speci-
fic mutation, although has been previously reported, is
of interest since it is the first MSH6 mutation reported
in a Greek family.
Detection of benign polymorphisms
Eleven intronic variants, three missense and four synon-
ymous changes have been identified in the MLH1,
MSH2 and MSH6 genes (Table 5). Two of the reported
polymorphisms (MSH2, c.646-46delC and MSH6, c.3678
A > G) are novel.
Table 2 Germline mutations detected in either of the MMR genes.
Family
ID
Gene Location Nucleotide change Protein effect Method used
F1376 MLH1 Exon 1 c.116+5G > C c.116_117ins227nt Sequencing
F656 MLH1 Exon 1 c.116+5G > C c.116_117ins227nt Sequencing
F263 MLH1 Exon 6 deletion of exon 6 p.Glu153[33]fsX8 MLPA/long range PCR
F33 MLH1 Intron 9 c.790+1G > A skipping of exons 9 and 10 Sequencing
F41 MLH1 Intron 9 c.790+1G > A skipping of exons 9 and 10 Sequencing
F74 MSH2 Exon 5 c.940C > T p.Gln314X Sequencing
F84 MSH2 Exon 7 c.1237C > T p.Gln413X Sequencing
F68 MSH2 Exon 7 c.1276G > C partial skipping of exon 8 Sequencing
F1278 MSH2 Exon 13 c.2089T > C p.Cys697Arg Sequencing
F39 MSH2 Exon 13 c.2131C > T p.Arg711X Sequencing
1SRB MSH2 Exon 13 c.2132G > C p.Arg711Pro Sequencing
F150 MSH6 Exon 5 c.3202 C > T p.Arg1068X Sequencing
F111 MSH2 Exon 12 possible duplication of exon 12 ? MLPA
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Page 4 of 12The MSH2, c.646-46delC, located in intron 3 of the
gene, has not been previously described. As it was
detected in one of our MLH1/MSH2 mutation-negative
patients, we tried to further characterize it through in
silico analysis (Table 4). The Human Splice Finder
(v.2.4) software demonstrated a significant variation in
t h eb r a n c hs i t eb e t w e e nt h e“wild type” and the
“mutant” sequence, while both the NNSplice (0.9)
http://www.fruitfly.org/seq_tools/splice.html and Net-
Gene2 http://www.cbs.dtu.dk/services/NetGene2/ soft-
ware packages presented no significant variation in
either of the major splice sites. Subsequently, RNA sam-
ple was collected from the index patient in order to
examine any possible alteration of the above variant on
the RNA level. cDNA prepared was amplified with pri-
mers spanning exons 2 to 5 of the MSH2 gene and
revealed the presence of one discernible band corre-
sponding to the wild type transcript (data not shown).
Therefore, it is obvious that the MSH2, c.646-46delC is
a non-pathogenic variation.
Gene dosage alterations
The eleven families tested negative for point mutations
were screened for the presence of large genomic rear-
rangements using MLPA. The MLPA analysis indicated
the presence of genomic rearrangements in two out of
twelve families. Particularly, one deletion encompassing
exon 6 of the MLH1 gene (c.454-?_545+?del) and one
duplication involving exon 12 of the MSH2 gene
(c.1760-?_2005+?dup) have been demonstrated.
The MLH1, c.454-?_545+?del was confirmed through
an individual second MLPA experiment which involved
the proband of the family (263), as well as one affected
and one unaffected first-degree relative (Figure 2). Sub-
sequently, a long range PCR was performed using a
sense primer located in exon 5 and an antisense primer
Figure 1 F41 pedigree. The F41 family carries the splice donor site alteration (c.790+1G > A) in exon 9 of the MLH1 gene. Predominantly
colorectal and endometrial cancer cases are encountered across three successive generations, being diagnosed ≤ 50y, thus this family fulfills the
Amsterdam criteria II. Furthermore, two metachronous cases of cancer were reported, which is another clinical feature of Lynch syndrome.
Particularly, the proband developed 2
nd primary colorectal cancer at 77y, while one of her daughters developed colorectal cancer at 45y and
endometrial cancer at 58y. Regarding the cases of breast and thyroid cancer reported, it seems that they are not part of Lynch syndrome’s
clinical manifestations, as the index patients do not carry the particular mutation running in the family. (wt/wt: homozygous for the wild type
allele, wt/mut: heterozygous for the mutant allele).
Thodi et al. BMC Cancer 2010, 10:544
http://www.biomedcentral.com/1471-2407/10/544
Page 5 of 12located in intron 7, which preferentially amplified a
smaller fragment of about 2.5 kb, instead of the
expected wild type fragment of 4937 bp (figure 3). The
2.5 kb fragment was subjected to sequencing in order to
uncover the flanking regions of the deleted segment.
Then, the 2.5 kb fragment was further amplified using
various combinations of intronic primers. Sequencing of
the smaller segments produced revealed the boundaries
of the deletion, starting between nucleotides 157967-
158005 in intron 5 and ends between nucleotides
160376-160414 in intron 6 (GenBank Accession number
AC011816). The breakpoints belong to AluSx_C repeats
according to the results of RepeatMasker http://www.
repeatmasker.org/cgi-bin/WEBRepeatMasker (Figure 3).
The exact breakpoints could not be determined due to
the presence of two identical 33 bp sequences located
within the AluSx_C elements which flank the deletion.
In order to assess the frequency of the MLH1,c . 4 5 4 - ?
_545+?del mutation in the Greek population, 951 unse-
lected sporadic CRC cases were screened using diagnos-
tic primers. The specific deletion was not detected
among these samples, indicating that it is not a recur-
rent mutation in the context of the Greek population.
In the case of the duplication of exon 12 of the MSH2
gene identified by MLPA, the results have been con-
firmed by a second individual MLPA experiment, but it
was not possible to be confirmed by another method.
Discussion and Conclusions
Lynch syndrome is a heterogeneous disorder in respects
to its molecular basis, as well as its phenotypic expres-
sion. Therefore, the selection of the putative mutation
carriers as well as the detection of the causative germ-
line alterations is a challenging task. A variety of point
mutations, such as substitutions, small insertions/dele-
tions and splice site alterations, as well as large genomic
rearrangements have been reported in the international
InSiGHT (LOVD) database [10]. Particularly, genomic
deletions account for approximately 10% of MLH1 and
MSH2 mutations, while genomic duplications have been
observed in approximately 1% of the Lynch syndrome
cases [11,22]. Furthermore, the fact that there are multi-
ple susceptible genes that predispose to Lynch syn-
drome, immunohistochemistry and/or MSI should be
used, where possible, as a pre-screening method to suc-
cessfully identify the high risk families. In our series of
Table 3 In silico analysis of novel mutation MSH2, p.Arg711Pro located in exon 13.
Methods of in silico
analysis
Result Comments
SIFT score 0.00®pathogenic If SIFT score < .05 then the aa substitution is predicted to affect protein
function
PolyPhen Probably damaging (3.071)®pathogenic If PolyPhen score > 2 then the aa substitution is predicted to affect
protein function
MAPP-MMR 40.700®pathogenic If MAPP-MMR score > 4.55 then the aa substitution is predicted to affect
protein function
NNSplice (0.9) SD: 1.00/1.00 No
SA: 0.95/0.95 Change
Scores predicted for the wt seq/score predicted for the mut seq
NetGene2 Server SD: 0.58/0.62 No
SA: 0.71/0.71 Change
Scores predicted for the wt seq/score predicted for the mut seq
Human Splice Finder v2.4
(HSF)
**
Rescue ESE
PESE octamers No
difference
ESS (Wang et al)
Fas-Ess hexamers
PESS octamers
IIEs (Zhang et al)
hnRP motifs
SD: 74.29/74.4
SA (c.2123):76.67/86.97
SA (c.2126):75.87/79.36
BP:81.68/86.61
Scores predicted for the wt seq/score predicted for the mut seq
ESE Finder:c.2129 SF2/ASF (IgM-BRCA1)®
new site
EIEs (Zhang et al): c.2127®new site
ESE from HSF: c.2132 9G8)®broken site
Silencer motifs (Sironi et al): c.2127®new
site
Other splicing motifs (Goren et al):
c.2130®new site
*SD: splice donor, SA: splice acceptor, BP: branch point aa: aminoacid.
**These algorithms are included in the HSF analysis.
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were not available and therefore, direct sequencing ana-
lysis of the MMR genes was performed.
Nine pathogenic point mutations and one genomic
rearrangement have been detected in twelve out of
seventeen (70.5%) AMS
+ families studied. A 29.5% of
AMS
+ families that included at least two colorectal or
other Lynch syndrome-associated cancer cases remained
unresolved. Additionally, no deleterious mutations were
detected in patients with young age of onset for CRC,
i.e. < 40 years, but with no family history. Our results
coincide with observations of previous studies which
have demonstrated that a proportion as high as 50% of
AMS
+ families harbour no pathogenic mutations in
either of the major MMR genes, namely MLH1 and
MSH2 genes [9]. Nevertheless, the detection rate among
AMS
+ families was much higher than in families
selected upon Bethesda guidelines, indicating the already
reported higher specificity of the modified Amsterdam
criteria in clinical practice.
Table 4 In silico analysis of novel sequence variations.
Gene (exon/
intron)
Nucleotide
change
Method Result Comments
MSH2 (exon 7) c.1276G > A Human Splice Finder
(v.2.4)
(HSF)
(*)
EIEs (Zhang et al) No
Rescue ESE change
PESE octamers/no
ESS (Wang et al) motif
PESS octamers found
IIEs (Zhang et al)
Other splicing motifs
(Goren et al)
“wt” donor site broken (84.7/73.68) Scores predicted for the wt seq/
score predicted for the mut seq
ESE Finder: c.1274 (SRp55)®new site
Rescue ESE: c.1271/c.1272®site broken
ESE from HSF: c.1273/c.1276 (9G8)®site broken
Silencer motifs (Sironi et al): c.1271/
c.1272®site broken
Fas-Ess hexamers: c.1275®site broken
hnRNP motifs: c.1273/c.1274 (hnRNP A1)®site
broken
NNSplice (0.9) “wt” donor site broken (0.91/-) Scores predicted for the wt seq/
score predicted for the mut seq
NetGene2 Server “wt” donor site broken (0.83/-) Scores predicted for the wt seq/
score predicted for the mut seq
MSH2 (intron 3) c.646/46delC Human Splice Finder
(v.2.4)
(HSF)
(*)
ESE Finder
Rescue ESE
PESE octamers
EIEs (Zhang et al) No
ESE from HSF change
Silencer motifs/no
(Sironi et al) motif
ESS (Wang et al) found
IIEs (Zhang et al)
hnRNP motifs
Other splicing motifs
(Goren et al)
Variation in one of the potential branch points
(c.646-48) (79.39/23.83)
Scores predicted for the wt seq/
score predicted for the mut seq
PESS octamers: c.646-49 (46.39/87.56)/c.646-
46®new site
NNSplice (0.9) SD: 0.90/0.90 No
SA: 0.90/0.91 change
Scores predicted for the wt seq/
score predicted for the mut seq
NetGene2 Server SD: 0.76/0.76 No
SA: 0.23/0.25 change
Scores predicted for the wt seq/
score predicted for the mut seq
(*) these algorithms are included in the HSF analysis.
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Page 7 of 12Since the particular study includes a relatively small
sample size, which can be a limitation when trying to
provide a complete mutational spectrum, all available
information on Greek putative Lynch syndrome families
have been combined [15]. Thirty-three families have
been screened for the presence of germline mutations in
the MLH1 and MSH2 genes, while thirteen of them
have been screened for the presence of germline muta-
tions in the MSH6 gene. Sixteen mutations have been
detected in eighteen of these families (Figure 4). To the
best of our knowledge, eight of the pathogenic muta-
tions recorded have never been described before.
Genomic rearrangements in the MLH1 and MSH2
genes represent 6% of the mutations identified in
Greece, a percentage that falls within the range reported
previously [9,22-25]. More specifically, in a German
patients’ cohort genomic deletions account for 10.6% of
colorectal cancer families, while in the Dutch population
genomic aberrations are encountered in 6.5% of AMS
+
families [23,24]. If only AMS
+ families are taken into
account, this proportion rises up to 8.3%, which is in
accordance with the observation made by Martínez-Bou-
zas et al [26]. Nonsense mutations and splice site
changes seem to prevail among point alterations identi-
fied in the Greek patients’ cohort. A quite interesting
finding of this study is the high rate of novel mutations,
which is calculated to be 53.3%, highlighting the distinct
heterogeneous nature of the Greek mutational spectrum
of the MLH1 and MSH2 genes.
Despite the aforementioned heterogeneity, two of the
mutations described, the MLH1, c.790+1G > A transition
and the MLH1, c.116+5G > C transversion were detected
in two distinct families during this study. The MLH1,
c.790+1G > A has been reported several times in differ-
ent populations and further analysis is required in order
to investigate the possible founder effect of this mutation
within the Greek or Cypriot population. The extensive
clustering of cancer cases within members of family 41 is
of particular interest, since thirteen family members
spread across three successive generations were diag-
nosed with five different cancer types. Interestingly, two
of the family members were diagnosed with breast and
thyroid cancer, respectively. These two types of cancer
are not typical phenotypic features of the Lynch syn-
drome. Both patients were genotyped and found not to
harbour the particular pathogenic mutation, indicating
that they were probably sporadic cancer cases. On the
contrary, other reports have been able to identify breast
cancer in MMR mutation carriers, enhancing the theory
that breast cancer can be a rare phenotypic feature of
Lynch syndrome [27-31].
On the other hand, the MLH1,c . 1 1 6 + 5 G>Ch a s
been reported only once before [16]. There is a possibi-
lity that the two families (F656, F1376) harbouring the
MLH1, c.116+5G > C mutation may be related, but it
was not feasible to track down all the family relatives,
since most of them live abroad. Further investigations
are required in order to elucidate whether the particular
alteration has a founder effect within the Greek
population.
The aforementioned data underscore the heterogeneity
of the MLH1 and MSH2 mutational spectrum in the
Table 5 Polymorphisms in either of the major MMR genes
Gene Location Nucleotide change Protein effect Families with the variant
MLH1 Intron 6 c.545+72T > A N.A 2
Exon 8 c.655A > G p.Ile219Val 12*
Intron 14 c.1668-19A > G N.A 6*
MSH2 Intron 1 c.211+8G > C N.A 2
Intron 1 c.211+9C > G N.A 4
Intron 3 c.646-46delC N.A 1
Exon 6 c.965G > A p.Gly322Asp 6
Intron 10 c.1661+12G > A N.A 14*
Intron 12 c.2006-6T > C N.A 9*
MSH6 Intron 1 c.261-36 A > G N.A. 2
Exon 1 c.116 G > A p.Gly39Glu 2
Exon 1 c.186 C > A p. Arg62Arg 2*
Exon 2 c.276 A > G p.Pro92Pro 4*
Exon 3 c.540 T > C p.Asp180Asp 4*
Intron 4 c.3173-101 C > G N.A. 1
Exon 5 c.3438+14 A > T N.A. 8*
Intron 7 c.3646+29_3646+32delCTAT N.A. 3*
Intron 8 c.3802-40 C > G N.A. 8*
Exon 8 c.3678 A > G p.Ala1226Ala 1
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Page 8 of 12Greek population, since each Greek family harbours a
distinct deleterious germline mutation, which can be of
any type. Furthermore, the first germline pathogenic
mutation in MSH6 gene in a Greek family is reported
here. Therefore, a combination of techniques that will
be able to detect both small size alterations within the
three genes and large deletions/insertions is required for
routine genetic testing of putative Lynch syndrome
patients, which is in accordance with other studies.
Moreover, we have achieved to determine the break-
points of the MLH1, c.454-?_545+?del and subsequently
to develop diagnostic primers for its rapid detection.
This deletion was described initially by Viel and her col-
leagues [32] and has been reported several times since
then. The possible founder effect of the specific
mutation within the Greek population has been
excluded when 951 unselected colorectal cancer cases
were screened and no carriers of the specific mutation
have been identified.
It is of great significance to obtain systematically data
about the exact nature and frequency of the pathogenic
mutations encountered in a particular patients’ cohort,
in order to customize the genetic testing to the popula-
tion’ s needs, which will eventually result in the reduc-
tion of the high cost of genetic testing along with the
optimization of the detection rate.
Our results indicate the distinct, heterogeneous nature
of Lynch syndrome’s associated mutations in a Greek
colorectal cancer patients’ c o h o r t ,a sw e l la st h es i g n i f i -
cant contribution of Amsterdam criteria in the
Figure 2 Identification of the MLH1, c.454-?_545+?del by MLPA and its breakpoint analysis. The electrophoregram of the index proband
of 263CRC family in comparison to a control sample is depicted. The two-fold decrease in height of the peak corresponding to exon 6 of the
MLH1 gene is indicated by the green arrows.
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Page 9 of 12Figure 3 Breakpoint analysis of the MLH1, c.454-?_545+?del. The products after long range PCR are shown in the upper part of the figure.
In the first two lanes corresponding to DNA samples of the 263CRC family members we obtained a discernible band of ~2.5 kb, as well as a
fainted band with the expected size of ~5 kb while in the third lane with control DNA sample we got only the band of ~5 kb which
corresponds to the expected “wt” allele. Lane 4: 100 bp ladder, lane 5: negative control, lane 6: 1 kB ladder. The PCR product obtained by the
combination of F3 and R1 primers was sequenced with R1 and revealed the deletion breakpoints, which are indicated by purple arrows upon
the chromatogram. The size and the boundaries of the deletion are depicted schematically in the lower part of the figure.
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Page 10 of 12identification of putative Lynch syndrome families. Con-
sequently, the compilation of an accurate and detailed
family history by the physician is a critical step for the
diagnosis of Lynch syndrome.
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